<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585207</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0964</org_study_id>
    <secondary_id>11-01864</secondary_id>
    <nct_id>NCT01585207</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder</brief_title>
  <official_title>Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara J. Coffey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vigabatrin, an unusual anti-seizure medication,
      will diminish the Tourette Disorder outbursts in young adults whose symptoms have persisted
      into adulthood and have not responded to usual treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are to 1) explore proof of concept that CPP-109 will reduce tics, and
      2) to obtain systematic data regarding dosing, safety and tolerability of CPP-109 in adults
      with treatment refractory TD. We will obtain preliminary data on estimate of effect size for
      tics using Cohen's d, calculating the difference between the two means (baseline and endpoint
      scores on the YGTSS), divided by the standard deviation of the difference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Severity Score on the Y-GTSS</measure>
    <time_frame>weekly from baseline to end of study (10weeks)</time_frame>
    <description>The Global Severity score is the sum of the Total Tic score and the TD Impairment score. It is rated by the Investigator on the Yale Global Tic Severity Score ( Y-GTSS, a widely accepted measure of drug efficacy in TD. Scale from 0- 100. Higher score indicates more impairment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Tourette's Disorder</condition>
  <arm_group>
    <arm_group_label>Vigabatrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets, bid for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vigabatrin</intervention_name>
    <description>3 tablets, bid for 8 weeks</description>
    <arm_group_label>Vigabatrin</arm_group_label>
    <other_name>CPP-109 Vigabatrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be between 18 and 35 years of age (inclusive) when informed consent is
             obtained.

          2. Subjects must meet full DSM-IV diagnostic criteria for TD by clinical interview on
             examination by a physician investigator, and confirmed by the Structured Clinical
             Interview for DSM (SCID-CT) for clinical trials.

          3. Subjects will have failed to respond to an adequate trial, as determined by the
             investigator, of clonidine, guanfacine, and a first generation (typical) and
             second-generation (atypical) neuroleptic medication in the past.

          4. Tics are causing significant distress or impairment, as determined by the subject and
             principal investigator, on the current treatment regimen.

          5. Laboratory results, including serum chemistries, hematology, and urinalysis, must show
             no significant abnormalities (significant is defined as laboratory values requiring
             acute medical intervention).

          6. Subjects will not undergo formal IQ testing, but must be of normal intelligence in the
             judgment of the investigator.

          7. Subjects must possess an educational level, degree of understanding and command of the
             English language to enable them to communicate suitably with the investigators and
             study coordinator, and to understand the nature of the study.

          8. Subjects must be considered reliable.

          9. Written informed consent of subjects is obtained.

        Exclusion Criteria:

          1. Subjects with organic brain disease, for example, traumatic brain injury residua.

          2. Subjects with a preexisting ophthalmologic condition.

          3. Subjects with or at high risk of other types of irreversible vision loss or who
             require other drugs associated with serious adverse ophthalmic effects such as
             retinopathy or glaucoma.

          4. Subjects meeting criteria for mental retardation as defined by the DSM-IV-TR.

          5. Subjects with a history of seizure disorder (other than febrile seizure).

          6. Subjects with history of Sydenham's Chorea.

          7. Subjects with autism, schizophrenia, other psychotic disorder, or bipolar disorder.

          8. Subjects with a primary diagnosis of a major mood disorder that requires ongoing
             psychiatric treatment.

          9. Subjects with a neurological disorder other than a tic disorder.

         10. Subjects with a major medical illness.

         11. Female subjects who are unwilling to use birth control or who are pregnant, as
             determined by serum pregnancy test at baseline assessment, or lactating.

         12. Subjects who have a past or current history of substance dependence and/or a current
             history of substance abuse or who fail baseline toxicology screen.

         13. Subjects who have any clinically significant abnormal laboratory result at baseline
             screening including EKG, or blood tests.

         14. Subjects who, in the opinion of the investigator, are unsuitable in any other way to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan D Brodie, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tics and Tourette's Clinical and Research Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 19, 2018</results_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Barbara J. Coffey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tourette's Disorder</keyword>
  <keyword>vigabatrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vigabatrin</title>
          <description>3 tablets, bid for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vigabatrin</title>
          <description>3 tablets, bid for 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.75" lower_limit="26" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>YGTSS (total tic)</title>
          <description>Yale Global Tic Severity Scale (YGTSS) - The Total Tic Score is a summation of the Total Motor Tic (0 -25) and Total Phonic Tic (0-25) Scores, full range 0 (No impairment) to 50 (Severe impairment)</description>
          <units>total tics</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Severity Score on the Y-GTSS</title>
        <description>The Global Severity score is the sum of the Total Tic score and the TD Impairment score. It is rated by the Investigator on the Yale Global Tic Severity Score ( Y-GTSS, a widely accepted measure of drug efficacy in TD. Scale from 0- 100. Higher score indicates more impairment.</description>
        <time_frame>weekly from baseline to end of study (10weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigabatrin</title>
            <description>3 tablets, bid for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Global Severity Score on the Y-GTSS</title>
          <description>The Global Severity score is the sum of the Total Tic score and the TD Impairment score. It is rated by the Investigator on the Yale Global Tic Severity Score ( Y-GTSS, a widely accepted measure of drug efficacy in TD. Scale from 0- 100. Higher score indicates more impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.25" lower_limit="76" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.75" lower_limit="75" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="36" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.75" lower_limit="63" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="57" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="49" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.75" lower_limit="44" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.88" lower_limit="44" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.33" lower_limit="53" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vigabatrin</title>
          <description>3 tablets, bid for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Appetite Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sleep Difficulties</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Daytime tiredness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Possible weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in OCD symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barbara J. Coffey</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-1663</phone>
      <email>Barbara.coffey@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

